newheader.jpg
 


Conference Menu

Overview

NEW!
Nanotech Business Perspective Forum

Agenda-Day One
Agenda-Day Two
Download PDF
View 2004 Attendees
Register
Poster
Hotel & Travel
Press Pass
Request Brochure
Send to a Colleague
 

Corporate Support:

 

Sponsoring Organization:

 

Lead Sponsoring Publications:

 Sponsoring Publications:

 

Web Partner:

 

Supporting Association:

 


Held immediately following the
4th Annual Systems Integration in Biodefense, August 24-25, 2005


Nanotech Business Perspective Forum*

Sunday, August 21

1:00-2:00pm Forum Registration

2:00-2:30 Nanotech Investment: Trends and Observations
Mr. Edward K. Moran, Director of Product Innovation/Leader, Nanotech Industry Practice Technology, Media & Telecommunications Group, Deloitte Services, LP
Although there is the popular perception that nanotech is being “hyped,” and that products are still years from commercialization, investors are waking up to the potential of nanotechnology. What sort of challenges do nanotechnology companies seeking financing face, what sort of metrics are VCs looking for, and what sort of exits can nanotech companies expect?

2:30-3:00 The New Face of Nanotechnology Finance
Mr. Scott Livingston - Managing Director, The Livingston Group - Axiom Capital Management
The classical path for entrepreneurs commercializing advanced technology has undergone significant change as a result of the boom and bust of the late 90s. The current angel/VC/IPO path is being challenged by new corporate financing structures, the current leaders on Wall Street are being challenged by a new group of firms with specific expertise in nanotechnology, and the established players in early stage finance are being challenged by a new type of institutional investor. Who are the new players and what are the new tools available to the nanotechnology entrepreneur and how will nanotechnology finance change over the next few years?

3:00-3:30 Refreshment Break

3:30-4:00  Drug Delivery to the Inner Ear
Dr. Stephen McCormack, President and Chief Executive Officer, NeuroSystec Corp.
NeuroSystec Corporation is a new combination therapy company that is developing unique, advanced products which deliver neuroactive compounds using pumps and formulation technologies to treat hearing disorders. By applying the advances in delivery systems to recently developed neuroactive compounds, we are joining two areas of scientific discovery in order to bring relief to people suffering from previously untreatable conditions. Tinnitus, a condition associated with hearing loss and with no method of treatment, is our first target indication. According to a CDC report 50 million Americans suffer from tinnitus and 2 million are disabled by the disease. This presentation will discuss the future of nanosystems for drug delivery and present an examination of clinical targets for inner ear disorders. 

4:00-4:30 Polymerized Liposomal Nanoparticles (PLNs): New, Targetable Delivery Vehicles for Anti-Inflammatory, Vaccine and Cancer Chemotherapeutic Applications
Dr. Jon O. Nagy, Vice President and Director of Medicinal Chemistry, NanoMed Technologies, LLC
NanoMed has developed a synthetic, non-viral nanoparticle technology embodying 1) a unique nanoparticle design platform, and 2) a customizable drug delivery system. The Polymerized Liposomal Nanoparticle (PLN) technology utilizes nanoparticles created using the self-assembling ability of a unique class of diacetylenic lipids that can be polymerized into stable, bimolecular membrane structures capable of delivering a drug payload. The PLN technology lends itself especially well to the display of multiple functionalities. These particles are comprised of individual lipid monomers part of which are functionalized for the purpose of targeting, and may include additional moieties to control other physical properties such as surface charge, polarity, and fluidity. Different functionalized lipids can be rapidly mixed and matched in an infinite number of combinations and relative concentrations to create tailor-made particles with desirable targeting and circulation properties. The nanoparticles are non-immunogenic, display no acute toxicity and can be highly concentrated. We are able to modulate the particle intracellular degradation and excretion rates by controlling the degree of polymerization.

4:30-5:00 The Nanomechanics of Protiveris’s Cantilever Arrays and Biosensor System
Dr. Gregory Kellogg, CTO, R&D, Protiveris Inc.
Nanomechanical cantilevers are extremely sensitive transducers of chemical and biological signals into mechanical motion. Protiveris’s VeriScan(tm) 3000 Biosensor System is the first nanomechanical cantilever reader capable of tracking the movement of an array of cantilevers in multiple assays wells. It can detect the motion of up to 64 cantilevers individually and simultaneously with resolutions of less than 1 nanometer of bending. Significantly, using optical detection techniques, the VeriScan 3000 Biosensor System can measure both stress related and mass related cantilever deflections. This technology offers real-time detection of biomolecular binding events, in a multiplex, label free format and at lower detection limits than existing techniques.

5:00 Close of Day One

5:10-5:30 Closing Comments

5:30 Close of Day One

4:30-5:30 Early Registration for Targeted Nanodelivery

*Separate Registration Required


foot.jpg


Cambridge Healthtech Institute| Beyond Genome | Bio-IT World | Biomarker World Congress | Cambridge Health Associates | Discovery On Target |
Health-IT World
| Bio-IT World Conference & Expo  | Molecular Medicine Tri-Conference | PEGS| PepTalk | Pharma DD
World Pharmaceutical Congress |

Your  Life Science Network

Cambridge Healthtech Institute  |  250 First Avenue  |  Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425
chi@healthtech.com